FDA Approves New Solution for Continuous Renal Replacement Therapy
A new FDA-approved drug will provide a new treatment option for adult and pediatric patients undergoing continuous renal replacement therapy.
A new FDA-approved drug will provide a new treatment option for adult and pediatric patients undergoing continuous renal replacement therapy (CRRT).
The FDA today approved Baxter International Inc’s Phoxillum Renal Replacement Solutions as a replacement solution for CRRT to correct electrolyte and acid-base imbalances. The drug can also be used in the case of drug poisoning when CRRT is used to remove dialyzable substances.
Baxter’s product is the only FDA-approved premixed solution including phosphate in a 5L bag, according to a Baxter press release.
For patients treated with CRRT, a common problem is an electrolyte disturbance where their blood has an abnormally low concentration of phosphate. This new single solution will help manage electrolytes during CRRT for many patients with acute kidney injury, which occurs often among hospitalized patients treated in intensive care.
The manufacturer estimates Phoxillum to be available in the second quarter of 2015.
''The approval of Phoxillum allows us to offer health care providers additional options in managing critically ill acute kidney injury patients treated with CRRT,'' said
, MD, vice president and renal therapeutic area lead at Baxter, in a press release. ''Introducing products like Phoxillum is part of Baxter’s commitment to offering health care providers a range of therapy options for patients.”